You are here

Approvable Letter Issued for Diquafosol Tetrasodium

DURHAM, NC - December 22, 2003 - Inspire Pharmaceuticals, Inc. (Nasdaq: ISPH) announced today that the U.S. Food and Drug Administration (FDA) has issued an approvable letter for diquafosol tetrasodium ophthalmic solution for the treatment of dry eye.

In the letter, the FDA requested that Inspire provide an additional clinical study. Inspire plans to meet with the FDA as soon as possible to determine whether study 03-108, which was completed after the New Drug Application was submitted, will be sufficient to meet this requirement. No other specific deficiencies were noted in the approvable letter. The letter indicated that comments on proposed labeling will be provided by the FDA when the clinical issues have been adequately addressed.

Christy L. Shaffer, Ph.D., Inspire's CEO, stated, "We are committed to working with the FDA to address the Agency's additional requirements for approval of this important product."

Source: Inspire Pharmaceuticals, Inc.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks